ISPOR 18th ANNUAL EUROPEAN CONGRESS CONCLUDES

Published Nov 23, 2015

ISPOR PROVIDES UNBIASED GLOBAL PLATFORM FOR  DIALOGUE AND CHANGE IN HEALTH CARE 

Princeton, NJ—November 23, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress recently concluded in Milan, Italy. Health ministries and government officials from more than 40 countries convened in Milan on 7-11 November, 2015 with over 5,000 ISPOR delegates, including health technology assessment (HTA) bodies and decision makers, leading researchers and academicians, public and private payers, patients and patient advocates, and other key health care stakeholders. The ISPOR European Congress provides an unbiased global platform for prominent experts involved in health economics and outcomes research (HEOR) to meet, share information, and discuss the use of HEOR research and scientific methods in health care decision making. The ISPOR Congress helps further ISPOR’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Highlights of the 2015 ISPOR European Congress comprised several seminal HTA summits, including the Health Technology Assessment (HTA) Roundtable, and a multi-stakeholder Patient Representatives Roundtable. Three notable plenary sessions were featured, including the 11 November session, Recommendations from the ISPOR Multi-Criteria Decision Analysis (MCDA) Emerging Good Practice Task Force and Remaining Controversies. MCDA is an increasingly important practice that uses a broad set of methodological approaches to assist healthcare decision making. MCDA has emerged as a important assessment tool in an era of expensive but valuable health technologies. The ISPOR MCDA Task Force Recommendations are the subject of a report that will be published in early 2016 in Value in Health, the official journal of ISPOR. Information on ISPOR’s MCDA in Health Care Decision Making Emerging Good Practices Task Force may be found at http://www.ispor.org/TaskForces/Multi-Criteria-Decision-Analysis-GRP.asp. “ISPOR has become the ‘network of networks,’ leading the effort to facilitate global communication and collaboration around the use of HEOR to improve decision-making for health globally,” noted ISPOR CEO, Nancy Berg. “The ISPOR European Congress is a vital platform to drive critical conversations among leading health economists, scientists, researchers, academicians, health care bodies and decision makers, patients, and other key stakeholders, and features a virtual ‘who’s who’ in the field.” This year’s influential Congress drew a total of 5,229 delegates from over 90 countries—a 9% increase over last year’s European Congress. The Congress was co-chaired by François Meyer, MD, Advisor to the President, International Affairs, French National Authority for Health (HAS), Saint-Denis La Plaine, France and Lorenzo G. Mantovani, DSc, Associate Professor of Public Health, Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy. Released presentations from the ISPOR 18th Annual European Congress are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan. ISPOR also recognized a number of 2015 Award Program recipients at the Congress. Notably, the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award was presented to Professor Anthony John (Tony) Culyer, CBE, Hon DEcon, FMedSci, Emeritus Professor of Economics, University of York, UK, who received a standing ovation from the Congress delegates. ISPOR’s Research Presentation Podium and Poster Awards were also presented at the Congress.

###

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×